ArticleCellular and molecular gastroenterology and hepatology2026
Trimethylamine N-Oxide, a Bariatric Surgery-Associated Host-Microbial Cometabolite, Reduces Colonic Tumorigenesis in a Sex-Dependent Manner.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND &
aimsTrimethylamine N-oxide is a host-microbial cometabolite that significantly increases following Roux-en-Y gastric bypass. Although trimethylamine N-oxide is associated with cardiovascular diseases, its role in colorectal cancer remains unclear.
methodsFabplCre;Apc
resultsTrimethylamine N-oxide supplementation significantly reduced the colonic tumor load in male, but not female, mice. Consistently, dietary trimethylamine N-oxide resulted in higher retention of circulating trimethylamine N-oxide in males, which was significantly and inversely correlated with tumor loads. Furthermore, tumor necrosis factor-α-expressing cell frequencies in the colonic intraepithelial lymphocytes were significantly lower in trimethylamine N-oxide-supplemented male mice compared with controls, suggesting that circulating trimethylamine N-oxide could play a protective effect against colonic tumor growth via down-regulation of tumor necrosis factor-α-expressing cells. This was supported by in vitro observations that trimethylamine N-oxide reduced lipopolysaccharide-stimulated tumor necrosis factor-α production from macrophages. Trimethylamine N-oxide exerted no effects on cell proliferation (Ki67) and DNA damage (γH2AX) of HCT-116 cells.
conclusionsOur study leads us to conclude that higher retention of circulating trimethylamine N-oxide has a protective effect against colorectal cancer in a sex-dependent manner, highlighting the importance of understanding the complex relationship among the concentrations of host-microbial cometabolite trimethylamine N-oxide, its systemic circulation, and its biological function in modulating colorectal cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.